-
Karenitecin
- names:
Karenitecin
- CAS号:
203923-89-1
MDL Number: - MF(分子式): C25H28N2O4Si MW(分子量): 448.59
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM002775-10mg | 10mg | 98.3% | ¥ 11475.00 | ¥ 11475.00 | 2-3天 | ¥ 0.00 | ||
| YZM002775-5mg | 5mg | 98.3% | ¥ 7150.00 | ¥ 7150.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 203923-89-1 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C25H28N2O4Si |
| 分子量 Molecular Weight | 448.59 |
| 溶解度Solubility | |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Karenitecin(CAS:203923-89-1)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | Karenitecin (Cositecan) 为拓扑异构酶 I (topoisomerase I) 抑制剂,具有高效的抗肿瘤活性 |
| Introduction | Karenitecin (Cositecan) is atopoisomerase Iinhibitor, with potent antiancer activity. |
| Application1 | |
| Application2 | |
| Application3 |
Karenitecin (Cositecan) 为拓扑异构酶 I (topoisomerase I) 抑制剂,具有高效的抗肿瘤活性。Karenitecin (Cositecan) is atopoisomerase Iinhibitor, with potent anti-cancer activity.
【1】.Yin MB, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9.
【2】.Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6.
【2】.Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


